Using contemporary therapeutic approaches, including stem cell transplantation (SCT), roughly 50% of young patients with acute myeloid leukemia (AML) can achieve long-lasting complete remissions (CRs). The individual prognosis of a patient depends, at least in part, on specific cytogenetic and molecular abnormalities. Genetic alterations in the nucleophosmin-(NPM)-1-gene are usually associated with a favorable prognosis, as long as they occur in the absence of FLT3-ITD mutations.
1 NPM1 appears to be more stable than FLT3-ITD mutations during the course of the disease and may therefore be used as a marker for minimal residual disease (MRD). 2 Increasing MRD levels after achieving CR are nearly uniformly followed by rapid overt AML relapse. 3 Thereafter, a second CR may be achieved in some patients using intensive salvage chemotherapies. These approaches are often accompanied by significant toxicities and can therefore be offered only to a subset of medically fit patients. Furthermore, only a minority of patients will achieve longlasting remissions under these circumstances even when treated with allogeneic SCT. This may be due to the fact that leukemic burden in relapsed patients is often too high to be controlled by chemotherapy and later by graft-versus-leukemia effects. Therefore, prevention of overt relapse by MRD-guided therapeutic interventions seems to be a reasonable approach. The possible agents for bridging patients with molecular relapse to allogeneic SCT should, in principle, fulfill two prerequisites: First, they should quickly and effectively prevent overt relapse. Second, they must not cause significant extramedullary toxicities that might render the patient unfit for transplantation. In fact, demethylating agents seem to meet both requirements. 5-aza-2-deoxycytidine and 5-azacytidine (aza) are clinically active in overt AML and MDS, respectively. 4, 5 Toxicity is rather modest, with myelosuppression and nausea being the most frequent side effects. Both drugs have not been used so far in the treatment of MRD. Nevertheless, the above-mentioned therapeutic effectiveness and favorable risk profile prompted us to use 5-aza in a patient with molecular relapse of NPM1 þ AML after previous induction chemotherapy followed by autologous transplantation.
A 56-year-old woman was diagnosed with AML FAB subtype M2 with an NPM1 mutation (type A) and an FLT3-ITD mutation (ratio of mutant FLT3 to wt FLT3 ¼ 0.61). Initially she presented with hyperleukocytosis (84 000/ml) and was treated with double-induction chemotherapy using standard-dose cytarabin and daunorubicin ('3 þ 7'). Early treatment assessment showed good response (o5% blasts). Complete hematological remission (CR) was observed after the second induction therapy. Further, stem cells were harvested after one cycle of consolidation therapy using high-dose cytarabin (2 Â 3 g/m 2 /day on days 1, 3 and 5). Four months after induction therapy, the patient received an autologous SCT after myeloablative conditioning (busulphan and cyclophosphamide).
Two months later CR could be documented, whereas NPM1 mutation was still detectable at a very low NPM1/abl ratio ( Figure 1) . Interestingly, the FLT3-ITD mutation became undetectable during induction therapy and remained negative throughout the rest of the treatment course. At the beginning of month 5 after autologous SCT, the patient was still in CR, but a significant increase in NPM1/abl ratio was documented. A month later, the NPM1/abl ratio showed a further nearly 2-log increase. Unfortunately, no suitable matched donor could be identified. To prevent overt relapse, 5-aza was started at a dose of 75 mg/m 2 /day (days 1-7). This treatment was well tolerated and a second cycle was administered on day 29. During this cycle the patient experienced an episode of nonfebrile grade 4 neutropenia and was therefore treated with pegfilgastrime. After this cycle, the bone marrow specimen showed normal cellularity and blast content (0.5%). The NPM1/abl ratio went down to low levels again. After a third cycle of 5-aza, a further decrease in the NPM1/abl ratio was observed. Therefore, the patient was finally offered a haploidentical bone marrow transplant from her daughter 5 months after diagnosis of molecular relapse. Conditioning was performed as described by O'Donnell et al. 6 On day 20 after allogeneic SCT, the patient could be discharged with documented stable engraftment and in the absence of signs of graft-versus-host disease (GvHD). She is currently alive and well. NPM1 negativity was observed on day 24 after allogeneic SCT in the peripheral blood.
This case shows that an MRD-triggered treatment approach using 5-aza in NPM1-mutation-positive AML can successfully M Wermke, C Thiede, A Kiani, G Ehninger, M Bornhäuser and U Platzbecker University Hospital Carl-Gustav-Carus, Medical Clinic I, Dresden, Germany E-mail: uwe.platzbecker@uniklinikum-dresden.de Fludarabine phosphate is among the most active drugs in the treatment of B-Cell Chronic Lymphocytic Leukemia (B-CLL), and as monotherapy, or in combination with cyclophosphamide and rituximab, has been widely adopted as frontline therapy for this disease. Pharmacokinetic studies show that oral fludarabine at a dose of 90 mg/m 2 /day produces an AUC (0À24 h) (AUC standing for area under the curve) comparable to that achieved with an intravenous dose of 50 mg/m 2 /day but with a lower C max 1 with a reported efficacy comparable to the intravenous drug. 2 In view of the convenience of administration and potential impact on resource utilization, the National Cancer Institute of Canada Clinical Trials Group initiated a phase II study of oral fludarabine in previously untreated patients with B-CLL who had an indication for therapy. The trial accrued 126 patients between 2002 and 2004. Confirmation of the diagnosis by flow cytometry was required. Analyses of known prognostic and predictive biomarkers including cytogenetic abnormalities, ZAP-70 expression and IgV H mutational status were performed. Cytogenetic abnormalities in peripheral blood mononuclear cells were identified by interphase FISH. The loci tested were ATM at 11q22.3, D135319 at 13q14.3, D12Z1 at 12p11.1-q11.1, and p53 at 17p13.1. A 13q34-specific sequence probe distinguished between monoallelic or biallelic loss and monosomy for chromosome 13.
All patients received oral fludarabine phosphate at a dose of 40 mg/m 2 /day for 5 days every 28 days for a planned six cycles, to a maximum of 8 cycles for patients not in CR after 6 cycles. Allopurinol was recommended for lymphocytosis X100 Â 10 9 /l at the institution of therapy and hematopoietic growth factor support to permit scheduled dose delivery was not allowed. Dose reductions for hematologic toxicity graded according to the National Cancer Institute Working Group (NCI-WG) criteria were made starting in the second cycle. 3 All patients receiving X1 cycle of therapy were evaluable for response and treatment responses were determined according to NCI-WG criteria. The primary efficacy end point was the overall response rate (CR þ PR) at the time of treatment completion analyzed on an intent-to-treat basis.
Cytogenetic abnormalities were detectable in 80% of cases, consistent with the rates of 77-82% reported in previously untreated and treated patients 4, 5 (Table 1) . Del 13q was the most common genetic abnormality (58%), followed by del 11q (23%), trisomy 12 (16%), and del 17p (5%) with 31% of patients having 41 abnormality.
IgV H sequencing on 101 samples showed an unmutated status (498% homology to known IgV H genes) in 62 patients and a mutated status in 39. ZAP-70 expression was evaluated in 125 cases with 55 positive (44%) and 70 negative (56%). ZAP-70 was expressed in 40 of 62 cases (65%) with unmutated IgV H , compared with 5 of 39 cases (12.8%) with mutated IgV H .
